178 related articles for article (PubMed ID: 25054967)
1. Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study.
Campos RA; Valle SO; França AT; Cordeiro E; Serpa FS; Mello YF; Malheiros T; Toledo E; Mansour E; Fusaro G; Grumach AS
Sao Paulo Med J; 2014; 132(5):261-5. PubMed ID: 25054967
[TBL] [Abstract][Full Text] [Related]
2. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.
Lumry WR; Farkas H; Moldovan D; Toubi E; Baptista J; Craig T; Riedl M
Int Arch Allergy Immunol; 2015; 168(1):44-55. PubMed ID: 26556097
[TBL] [Abstract][Full Text] [Related]
3. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.
Farkas H; Reshef A; Aberer W; Caballero T; McCarthy L; Hao J; Nothaft W; Schranz J; Bernstein JA; Li HH
J Allergy Clin Immunol Pract; 2017; 5(6):1671-1678.e2. PubMed ID: 28601641
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility.
Otani IM; Lumry WR; Hurwitz S; Li HH; Craig TJ; Holtzman NS; Iandoli MI; Tucker J; Riedl MA; Zuraw BL; Banerji A
J Allergy Clin Immunol Pract; 2017; 5(2):442-447.e1. PubMed ID: 27818136
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, pharmacokinetics, and safety of icatibant for the treatment of Japanese patients with an acute attack of hereditary angioedema: A phase 3 open-label study.
Hide M; Fukunaga A; Maehara J; Eto K; Hao J; Vardi M; Nomoto Y
Allergol Int; 2020 Apr; 69(2):268-273. PubMed ID: 31672405
[TBL] [Abstract][Full Text] [Related]
6. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant.
Bouillet L; Boccon-Gibod I; Launay D; Gompel A; Kanny G; Fabien V; Fain O;
Immun Inflamm Dis; 2017 Mar; 5(1):29-36. PubMed ID: 28250922
[TBL] [Abstract][Full Text] [Related]
7. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.
Baş M; Greve J; Hoffmann TK; Reshef A; Aberer W; Maurer M; Kivity S; Farkas H; Floccard B; Arcoleo F; Martin L; Sitkauskiene B; Bouillet L; Schmid-Grendelmeier P; Li H; Zanichelli A
Allergy; 2013 Nov; 68(11):1452-9. PubMed ID: 24111645
[TBL] [Abstract][Full Text] [Related]
8. Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey.
Maurer M; Bork K; Martinez-Saguer I; Aygören-Pürsün E; Botha J; Andresen I; Magerl M
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):163-169. PubMed ID: 30176179
[TBL] [Abstract][Full Text] [Related]
9. Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals.
Hernández Fernandez de Rojas D; Ibañez E; Longhurst H; Maurer M; Fabien V; Aberer W; Bouillet L; Zanichelli A; Caballero T;
Int Arch Allergy Immunol; 2015; 167(1):21-8. PubMed ID: 26112099
[TBL] [Abstract][Full Text] [Related]
10. Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting.
Maurer M; Longhurst HJ; Fabien V; Li HH; Lumry WR
Allergy Asthma Proc; 2014; 35(5):377-81. PubMed ID: 25198193
[TBL] [Abstract][Full Text] [Related]
11. The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries.
Caballero T; Aberer W; Longhurst HJ; Maurer M; Zanichelli A; Perrin A; Bouillet L; Andresen I;
J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1214-1222. PubMed ID: 28370444
[TBL] [Abstract][Full Text] [Related]
12. First report of icatibant treatment in a pregnant patient with hereditary angioedema.
Farkas H; Kőhalmi KV; Veszeli N; Tóth F; Varga L
J Obstet Gynaecol Res; 2016 Aug; 42(8):1026-8. PubMed ID: 27093898
[TBL] [Abstract][Full Text] [Related]
13. [EFFICACY, PHARMACOKINETICS, AND SAFETY OF ICATIBANT FOR THE TREATMENT OF JAPANESE PATIENTS WITH AN ACUTE ATTACK OF HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
Hide M; Fukunaga A; Maehara J; Eto K; Hao J; Vardi M; Nomoto Y
Arerugi; 2018; 67(2):139-147. PubMed ID: 29553114
[TBL] [Abstract][Full Text] [Related]
14. Icatibant as acute treatment for hereditary angioedema in adults.
Farkas H
Expert Rev Clin Pharmacol; 2016 Jun; 9(6):779-88. PubMed ID: 27123689
[TBL] [Abstract][Full Text] [Related]
15. Icatibant for hereditary angioedema.
Gras J
Drugs Today (Barc); 2009 Dec; 45(12):855-64. PubMed ID: 20135020
[TBL] [Abstract][Full Text] [Related]
16. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.
Malbrán A; Riedl M; Ritchie B; Smith WB; Yang W; Banerji A; Hébert J; Gleich GJ; Hurewitz D; Jacobson KW; Bernstein JA; Khan DA; Kirkpatrick CH; Resnick D; Li H; Fernández Romero DS; Lumry W
Clin Exp Immunol; 2014 Aug; 177(2):544-53. PubMed ID: 24749847
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics and Exposure-Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema.
Wang Y; Jomphe C; Marier JF; Martin P
J Clin Pharmacol; 2021 Apr; 61(4):555-564. PubMed ID: 33091166
[TBL] [Abstract][Full Text] [Related]
18. Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.
Lumry WR; Li HH; Levy RJ; Potter PC; Farkas H; Moldovan D; Riedl M; Li H; Craig T; Bloom BJ; Reshef A
Ann Allergy Asthma Immunol; 2011 Dec; 107(6):529-37. PubMed ID: 22123383
[TBL] [Abstract][Full Text] [Related]
19. Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks.
Hide M; Horiuchi T; Ohsawa I; Andresen I; Fukunaga A
Allergol Int; 2021 Jan; 70(1):45-54. PubMed ID: 32919903
[TBL] [Abstract][Full Text] [Related]
20. Icatibant use in Brazilian patients with hereditary angioedema (HAE) type 1 or 2 and HAE with normal C1-INH levels: findings from the Icatibant Outcome Survey Registry Study.
Grumach AS; Henriques MT; Bardou MLD; Pontarolli DA; Botha J; Correa M;
An Bras Dermatol; 2022; 97(4):448-457. PubMed ID: 35654647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
